Hsu R, Brunet L, Fusco J, et al. Incidence of CKD With TDF and Non-TDF Containing Antiretroviral Regimens by Baseline D:A:D CKD Risk In People Living With HIV. Presented at: European AIDS Clinical Society (EACS)2019; Basel, Switzerland
Research Category: Oral Presentations
Changes in BMI associated with antiretroviral regimens in treatment-experienced, virologically suppressed individuals living with HIV
Mounzer K, Brunet L, Hsu R, et al. Changes in BMI associated with antiretroviral regimens in treatment-experienced, virologically suppressed individuals living with HIV. Presented at: IDWeek 2019; Washington, D.C
Virologic Failure In ART-Naive HIV Patients With High Pre-Therapy Viral Load Burden Initiating On Common Core Agents
Mills AM, Schulman KL, Fusco JS, et al. Virologic Failure In ART-Naive HIV Patients With High Pre-Therapy Viral Load Burden Initiating On Common Core Agents. Presented at: 10th IAS Conference on HIV Science (IAS 2019)2019; Mexico City, Mexico
Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions following initiation of commonly prescribed antiretrovirals
Lackey P, Brunet L, Fusco J, Vannappagari V, Ragone L, Fusco G. Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions following initiation of commonly prescribed antiretrovirals. Presented at: IDWeek 2018; Washington, D.C., USA
Hepatotoxicity associated with NNRTIs & NRTI backbones
Dieterich DT, Fusco JS, Becker SL, Balu RB, Fusco GP. Hepatotoxicity associated with NNRTIs & NRTI backbones. Oral Presentation. Abstract 30. 8th International Workshop on HIV Databases. Mar 2004, Montreux, Switzerland
Does it matter where you came from? Prognosis of patients starting potent therapy, according to initial response
Stern JAC, May M, Costagliola D, Pezzotti P, Ledergerber B, deWolf F, Lundgren J, Fusco JS, Staszewski S, Raffi F, Hogg RS, Phillips AN, Gill MJ, Fatkenheuer G, Chene G. Does it matter where you came from? Prognosis of patients starting potent therapy, according to initial response. Oral presentation. 10th Annual Congress on Retroviruses and Opportunistic Infections. Feb 2003, Boston, MA
Factors affecting CD4 count slope in patients with stable viral load following three class virologic failure
Ledergerber B, Lundgren JD, Fusco GP, Weber R, Wit F, Castelli F, Staszewski S, Hogg R, Walker AS, Petoumenos K, d’Arminio Monforte A, Mussini C, Lampe F, Gill MJ, Phillips AN. Factors affecting CD4 count slope in patients with stable viral load following three class virologic failure. Oral presentation. Session 27, 10th Annual Congress on Retroviruses and Opportunistic Infections. Feb 2003, Boston, MA
actors contributing to the success of ART following three class virological failure: the PLATO collaboration
Ledergerber B, Lundgren JD, Fusco GP, Weber R, Wit F, Castelli F, Staszewski S, Hogg R, Walker AS, PetoumenosK , D“Armenio Monforte A, Mussioni C, Lampe F, Gill MJ, Phillips A. Factors contributing to the success of ART following three class virological failure: the PLATO collaboration. Oral presentation 576. International AIDS Society Conference. July 2003, Paris, France
Assessment of global virological response to first HAART via convolutions
McKinnon E, Fusco JS, John M, Fusco GP, Becker SL, James I, Mallal S. Assessment of global virological response to first HAART via convolutions. Oral presentation. 7th International Workshop on HIV Databases. Mar 2003, Fiuggi, Italy
Antiretroviral therapy and cardiovascular disease in HIV infected individuals
Raffanti S, Arbogast P, Scarsella A, Becker SL, Fusco JS, Dieterich D, Fusco GP. Antiretroviral therapy and cardiovascular disease in HIV infected individuals. Oral presentation. 4th Annual Observational Database Meeting. 2003, Washington, D.C